Publications by authors named "R Hernandez-Alejandro"
Liver transplant (LT) for colorectal cancer liver metastases (CRLM) is increasingly popular, yet the ideal selection criteria remain unknown. Pretransplant positron emission tomography (PET) metabolic tumor volume (MTV) has been described as predicting recurrence, with a proposed cutoff of MTV ≥70 cm 3 . This approach has not been validated.
View Article and Find Full Text PDFWe report a case of a 55-year-old male with intrahepatic cholangiocarcinoma (iCCA) who underwent living donor liver transplantation (LDLT) after complete radiographic response on second-line pemigatinib. LDLT for iCCA is controversial, but recent reports have cited the potential benefit for patients with unresectable disease, especially those with disease stability after 6 months of systemic therapy. Concomitantly, genomic profiling has identified potentially treatable oncologic targets in iCCA.
View Article and Find Full Text PDFBackground: Recent advancements in cancer treatment and post-transplant management have expanded the population of living donor liver transplant (LDLT) candidates. We aimed to examine variations in public acceptance of LDLT based on patient diagnosis, including unresectable colorectal liver metastases (uCRLM).
Methods: A web-based survey collected demographic information and general perceptions about organ donation in different settings.
Living donor liver transplantation (LDLT) is a treatment option for select patients with unresectable colorectal liver metastasis. We describe our center's experience of patient selection, insurance approval, and outcomes after LDLT after first referral in March 2019. Of the 206 evaluated patients, 23 underwent LDLT.
View Article and Find Full Text PDFArticle Synopsis
- Post-liver transplant (LT) patients require immunosuppression to avoid organ rejection, but this increases the risk of tumor recurrence, particularly for patients with hepatocellular carcinoma (HCC).
- This study analyzed data from 1,406 HCC patients who underwent LT to assess the impact of varying levels of tacrolimus (FK) immunosuppression on cancer recurrence, finding that FK levels measured two weeks post-transplant were significantly associated with recurrence risk.
- Results indicate that personalized immunosuppression strategies should consider the timing and individual patient's risk factors (like tumor characteristics) to optimize outcomes after LT.